Table of Contents
Chemotherapy Research and Practice
Volume 2010 (2010), Article ID 524629, 8 pages
http://dx.doi.org/10.1155/2010/524629
Research Article

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?

1i3 Innovus, Medford, MA 02155, USA
2Global Health Outcomes, Lilly Corporate Center, Eli Lilly and Company, DC6831, Indianapolis, IN 46285, USA
3Boston Health Economics, Inc., Waltham, MA 02451, USA
4Institute for Clinical Evaluative Sciences, Toronto, ON, Canada M4N 3M5

Received 10 November 2009; Revised 17 May 2010; Accepted 16 June 2010

Academic Editor: Nagahiro Saijo

Copyright © 2010 Karen M. Clements et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, “Detailed guide: lung cancer—non-small cell,” February 2009, http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=15.
  2. R. S. Herbst, J. V. Heymach, and S. M. Lippman, “Molecular origins of cancer: lung cancer,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1367–1380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. American Cancer Society, “What is non-small cell lung cancer?” February 2009, http://www.cancer.org/docroot/CRI/content/CRI_2_2_1x_What_Is_Non-small_Cell_Lung_Cancer.asp?rnav=cri.
  4. D. S. Ettinger, G. Bepler, R. Bueno et al., “Non-small cell lung cancer. Clinical practice guideline in oncology,” Journal of the National Comprehensive Cancer Network, vol. 4, no. 6, pp. 548–582, 2006. View at Google Scholar · View at Scopus
  5. J. K. Weick, J. Crowley, R. B. Natale et al., “A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study,” Journal of Clinical Oncology, vol. 9, no. 7, pp. 1157–1162, 1991. View at Google Scholar · View at Scopus
  6. Non-small Cell Lung Cancer Collaborative Group, “Chemotherapy for non-small cell lung cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD002139, 2000. View at Google Scholar · View at Scopus
  7. J. R. Molina, A. A. Adjei, and J. R. Jett, “Advances in chemotherapy of non-small cell lung cancer,” Chest, vol. 130, no. 4, pp. 1211–1219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Scagliotti, N. Hanna, F. Fossella et al., “The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies,” Oncologist, vol. 14, no. 3, pp. 253–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. E. Ciuleanu, T. Brodowicz, C. P. Belani et al., “Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study,” Journal of Clinical Oncology, vol. 26, no. 20S, 2008, abstract 8011. View at Google Scholar
  10. G. Peng, R. G. Zinner, Y. Wang et al., “Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials,” Journal of Clinical Oncology, vol. 26, no. 20S, 2008, abstract 8096. View at Google Scholar
  11. Y. Ohe, Y. Ichinose, K. Nakagawa et al., “Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer,” Clinical Cancer Research, vol. 14, no. 13, pp. 4206–4212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. G. V. Scagliotti, P. Parikh, J. von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto, “Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 19, pp. 3852–3859, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Jiang, X. Liang, X. Zhou, R. Huang, and Z. Chu, “A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer,” Lung Cancer, vol. 57, no. 3, pp. 348–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Ardizzoni, L. Boni, M. Tiseo et al., “Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis,” Journal of the National Cancer Institute, vol. 99, no. 11, pp. 847–857, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. American Cancer Society, “Detailed guide: lung cancer—non-small cell. Treatment choices by stage for non-small cell lung cancer,” April 2009, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/lung-cancer–non-small-cell–treating-by-stage.
  18. S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato, “Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare,” Journal of Clinical Oncology, vol. 22, no. 24, pp. 4971–4978, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. F. R. Hirsch, A. Spreafico, S. Novello, M. D. Wood, L. Simms, and M. Papotti, “The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review,” Journal of Thoracic Oncology, vol. 3, no. 12, pp. 1468–1481, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. National Cancer Institute, “SEER-Medicare Publications,” August 2005, http://healthservices.cancer.gov/seermedicare/overview/publications.html.
  21. X. Du, J. L. Freeman, and J. S. Goodwin, “Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data,” Journal of Clinical Epidemiology, vol. 52, no. 5, pp. 463–470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Charlson, P. Pompei, K. A. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Google Scholar · View at Scopus
  23. R. A. Deyo, D. C. Cherkin, and M. A. Ciol, “Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases,” Journal of Clinical Epidemiology, vol. 45, no. 6, pp. 613–619, 1992. View at Publisher · View at Google Scholar · View at Scopus
  24. R. B. D'Agostino Jr. and R. B. D'Agostino Sr., “Estimating treatment effects using observational data,” Journal of the American Medical Association, vol. 297, no. 3, pp. 314–316, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. G. V. Scagliotti, F. De Marinis, M. Rinaldi et al., “Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4285–4291, 2002. View at Publisher · View at Google Scholar · View at Scopus